Last reviewed 2026-04-23 · How we verify

Placebo for Atogepant

This is a placebo control with no active pharmacological mechanism.

This is a placebo control with no active pharmacological mechanism. Used for Control arm in atogepant clinical trials for migraine prevention.

At a glance

Mechanism of action

Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (atogepant) through comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect beyond potential placebo response.

Approved indications

• Control arm in atogepant clinical trials for migraine prevention

Common side effects

No common side effects on file.

Key clinical trials

• Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (PHASE3)
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (PHASE3)
• Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (PHASE3)
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years (PHASE3)
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine (PHASE3)
• Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine (PHASE3)
• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. (PHASE3)
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.